CD26 inhibitors (Point Therapeutics)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameCD26 inhibitors (Point Therapeutics)
Drug Alias Nameimmunotherapeutics (Point Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsNeoplasmsAcquired Immunodeficiency Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTufts University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFortovia Therapeutics IncTufts University
Active IndicationsN/A
Inactive IndicationsNeoplasmsAcquired Immunodeficiency Syndrome

Other Information

ATC CodeN/A
Related LinksN/A